Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas. Bagot, M., Duvic, M., Vermeer, M., Porcu, P., Whittaker, S., Ram-Wolff, C., Paiva, C., Marie-Cardine, A., Bonnafous, C., Paturel, C., Moriette, F., Zerbib, R., Bensussan, A., Sicard, H., Pilz, K., Kim, Y. H. AMER SOC CLINICAL ONCOLOGY. 2016
View details for DOI 10.1200/JCO.2016.34.15_suppl.TPS2591
View details for Web of Science ID 000404665403190